key: cord-0286235-7voqfm3i
authors: Ciesla, Jessica; Moreno, Isreal; Munger, Joshua
title: TNFα-induced metabolic reprogramming drives an intrinsic anti-viral state
date: 2022-04-14
journal: bioRxiv
DOI: 10.1101/2022.04.14.488171
sha: 038f8597e048bb3f8f5a69594ae3ea78b206f45c
doc_id: 286235
cord_uid: 7voqfm3i

Cytokines induce an anti-viral state, yet many of the functional determinants responsible for limiting viral infection are poorly understood. Here, we find that TNFα induces significant metabolic remodeling that is critical for its anti-viral activity. Our data demonstrate that TNFα activates glycolysis through the induction of muscle-specific hexokinase (HK2). Further, we show that glycolysis is broadly important for TNFα-mediated anti-viral defense, as its inhibition attenuates TNFα’s ability to limit the replication of evolutionarily divergent viruses. Stable-isotope tracing revealed that TNFα-mediated glycolytic activation promotes the biosynthesis of UDP-sugars (essential precursors of protein glycosylation) and that inhibition of glycolysis prevents the accumulation of several glycosylated anti-viral proteins. Consistent with the importance of glucose-driven glycosylation, glycosyl-transferase inhibition also attenuated TNFα’s ability to promote the anti-viral cell state. Collectively, our data indicate that cytokine-mediated metabolic remodeling is an essential component of the anti-viral response.

TNFα treatment at multiple time points including fructose-6-phosphate, dihydroxyacetone 109 phosphate, and glyceraldehyde-3-phosphate (Fig. 2a) . Similarly, UDP-glucose of the hexosamine 110 pathway was induced at every time point analyzed (Fig. 2a) . For pentose phosphate metabolites: 111 sedoheptulose-7-phosphate was only induced at 24 hours post-TNFα treatment, whereas 112 erythrose-4-phosphate and ribose-phosphate were induced at all time points analyzed (Fig. 2a) .

The elevation of several glycolytic intermediates suggested that TNFα-treatment induced 115 glycolysis. To test this possibility, we analyzed the impact of TNFα on glucose consumption and 116 lactate secretion. Both glucose consumption and lactate secretion were substantially induced by 117 TNFα treatment (Fig. 2b & c) . Basal lactate secretion and TNFα-induced lactate secretion were 118 severely attenuated by treatment with the glycolytic inhibitor, 2-deoxyglucose (2DG) (Fig. 2c ).

Collectively, our data indicate that TNFα treatment induces glycolytic activation as part of a broad 120 metabolic remodeling.

TNFα-mediated glycolytic activation is important for its anti-viral activity. To examine how 123 glycolytic inhibition impacted TNFα-induced metabolic modulation, we analyzed the metabolomic 124 impact of 2DG co-treatment with TNFα via LC-MS/MS (Supplementary Table 3 ). PCA indicated 125 that the largest amount of data variance, i.e., 37.1% of the variance associated with PC1, 126 separated all 2DG treated from the non-2DG treated samples regardless of TNFα treatment (Fig. 127 3a). In the non-2DG treated samples, TNFα treated samples were separated from non-TNFα 128 treated samples along PC2 (Fig. 3a) . In contrast, co-treatment with 2DG largely collapsed this 129 separation between TNFα treated and non-TNFα treated samples along PC2 (Fig. 3a) . Similarly, 130 hierarchical clustering of the metabolic data primarily separated samples based on whether they 131 were 2DG treated or not (Fig. 3b) . Further, as would be expected, 2DG treatment reversed the 

To determine how TNFα-mediated glycolytic activation contributes to its ability to induce 136 the anti-viral state, we assessed how glycolytic inhibition impacted TNFα's ability to limit viral 137 infection. Pretreatment of cells with TNFα largely blocked the ability of HCMV to initiate infection 138 (Fig. 3d & e) . TNFα pretreatment in the presence of 2DG largely restored the ability of HCMV to 139 infect cells (Fig. 3d & e) . We also found that glucose starvation during TNFα pretreatment 

Given that TNFα is broadly anti-viral, we next sought to determine if TNFα's effects on 149 glycolysis was specific to limiting HCMV infection, or if a similar phenotype could be observed in 150 the context of evolutionary divergent viruses. To address this issue, we analyzed the replication 151 of two β-Coronaviruses, OC43 and SARS-CoV-2, in cells that had been pretreated with TNFα in 152 the presence or absence of 2DG. TNFα pretreatment was sufficient to restrict the RNA 153 accumulation of both OC43 and SARS-CoV-2 ( Fig. 3g & h) . TNFα pretreatment in the presence 154 of 2DG largely restored OC43 and SARS-CoV-2 RNA accumulation ( Fig. 3g & h) . These data 155 align with the results from HCMV infection and support that TNFα treatment broadly requires 156 glycolysis for its anti-viral activity.

analyzed the impact of TNFα treatment in the presence or absence of 2DG on the proteome. The 161 abundances of 3,780 unique proteins were identified in this study (Supplementary Table 4 ). From 162 this list, we extracted those involved in metabolism to study the differences in the abundance of 

GLUT1 was induced ~5-fold, and HK2 was induced ~2.5 fold in TNFα-treated samples relative to 172 vehicle (Fig. 4c ). In agreement with our proteomics data, HK2 mRNA was induced upon TNFα 173 treatment (Fig. 4d) , as was GLUT1 mRNA (Fig. 4e) . Immunoblot analysis showed HK2 and 174 GLUT1 proteins were ~40% and ~90% more abundant in TNFα treated cells, respectively ( Fig.   175 4g). No other glycolytic enzymes were significantly increased as a result of TNFα treatment, 176 however in contrast PFK-M and TIGAR levels were significantly reduced by TNFα treatment (Fig.   177 4b & c). We also sought to examine if TNFα could be inducing HIF1α expression given its role as 178 a glycolysis activator 27 . While Hif1α was not detected in the proteomics data set after 24 hours of 179 TNFα treatment, its mRNA levels were induced 2-fold at 8 hours post-TNFα treatment relative to 180 vehicle-treated samples (Fig. 4f ).

Given that HK2 is the muscle-specific hexokinase isoform, and is not thought to be 184 substantially expressed in fibroblasts, we sought to determine the importance of TNFα-induced 185 expression of this isoform for glycolytic activation. We targeted HK2 and HIF1α via CRISPR-Cas9 to assess their contributions to TNFα-mediated glycolytic activation and induction of an anti-viral 187 cell state. RNP-based Cas9 delivery successfully inactivated HK2, resulting in the loss of HK2 188 protein accumulation (Fig. 4h) . While Hif1α protein could not be detected by western blot, genomic 189 ablation of the HIF1A gene was confirmed via genomic sequence analysis, with a knockout-score 190 of 89% ( Supplementary Fig. 2) . Notably in HIF1A targeted cells, HK2 protein expression was 191 somewhat reduced, raising the possibility that HK2 could be regulated by Hif1α (Fig. 4h) 

suggesting that Hif1α may largely be dispensable for TNFα-mediated glycolytic activation.

We next tested if HK2 or Hif1α are necessary for TNFα to promote an anti-viral state. As TNFα's anti-viral activity, and thereby suggesting that enough glycolysis occurs in their absence 207 to enable TNFα-mediated viral inhibition. Our data suggest that while HK2 and Hif1α are not 208 essential for TNFα's anti-viral activity, they may play a role in restricting HCMV infection that is 209 independent of TNFα signaling. Table 4 ). PCA of the total proteomics data set 215 show that TNFα-treated samples in the presence or absence of 2DG segregated from non-TNFα 216 treated samples largely along PC2, whereas 2DG-treated samples segregated from non-2DG 217 treated samples along PC1 (Fig. 5a) . Notably, co-treatment with 2DG and TNFα blunted the 218 TNFα-induced response as indicated by a much-reduced shift along PC2. In contrast, co-219 treatment with 2DG and TNFα induced a larger leftward shift along PC1 than was observed with 220 2DG treatment alone (Fig. 5a) . These data suggest that 2DG treatment blunts the impact of TNFα 221 treatment on the proteome, and further that TNFα and 2DG co-treatment accelerates the 222 proteomic impact over 2DG alone.

To further explore the impact of 2DG treatment on TNFα-induced proteomic changes, we 225 analyzed the proteins whose abundances were significantly depleted or induced by co-treatment 226 with 2DG and TNFα relative to TNFα alone (Supplementary Table 4 .2 and 4.3, respectively).

Gene Ontology (GO) analysis indicated that proteins significantly up-regulated in response to 228 2DG+TNFα co-treatment relative to TNFα treatment alone belonged to a diverse array of 229 pathways including receptor-mediated endocytosis, the unfolded protein response, and various 

In contrast, the pathways associated with proteins that exhibited substantially lower levels during 232 2DG and TNFα co-treatment relative to TNFα alone shared a common theme, they are important 233 to the innate immune antiviral response (Fig. 5b, Supplementary Table 4 .2). These ontological 234 pathways included responses to IFN, defense responses to viruses, and regulation of viral 235 genome replication (Fig. 5b) . Approximately 33% of these proteins reduced in 2DG and TNFα co-236 treated cells included genes within the ontological pathway 'response to cytokine signaling' , e.g., IFIs, ISGs, as well as other critical viral defense genes, e.g., MX1, OAS53, SAMHD1, and global 238 innate regulators, e.g., STAT1 (Fig. 5c, Supplementary Fig. 4) . Additionally, 43% of these 239 substantially down-regulated proteins are glycosylated (Fig. 5c, Supplementary Fig. 4 ).

Collectively, these data indicate that restricting glycolysis during TNFα treatment prevents the 

GlcNAc) were more abundant in TNFα-treated cells (Fig. 6a) . These enzymes include UTP-252 glucose-1-phosphate uridylyl transferase (UGP2), which catalyzes the conversion of glucose-1-253 phosphate into UDP-Glc 28 ; dolichyl-phosphate beta-glucosyltransferase (ALG5), which initiates 254 biosynthesis of lipid-linked oligosaccharides for glycosylation in the ER membrane using UDP-255 Glc 29 ; and alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosamine transferase (MGAT1), 256 which promotes biosynthesis of N-Glycans for glycosylation using UDP-GlcNAc as a substrate 30 257 (Fig. 6a) . We find that UDP-Glc is ~3-fold more abundant in cells treated with TNFα, but UDP-

GlcNAc pools are unchanged (Fig. 6b) . To examine the turnover kinetics of these pools, we 

A key aspect of TNFα-induced glycolytic activation was the induction of HK2 expression, 290 which was subsequently found to be important for TNFα-mediated glycolytic activation (Fig. 4 ).

Previously, TNFα has been reported to induce HK2 in a murine skeletal muscle cell line 37 , but 292 little is known about how HK2 contributes to TNFα-associated activities. HK2 is canonically 293 thought of as the muscle-specific hexokinase isoform, although it's expression has also been 294 found to be induced in various tumor types 38 . In tumors it is thought to be important for cancer-295 cell survival through modulation of metabolic-associated stress responses 39 . While our results

indicate that TNFα induces HK2 expression, which we found to be important for TNFα-induced 297 glycolytic activation, its deletion did not restore viral infection in the face of TNFα treatment ( Fig.   298 4j). This suggests that HK2 is not essential for TNFα-mediated inhibition of HCMV plaque 299 formation, and that the amount of glycolysis that occurs in its absence is sufficient to support 300 TNFα's antiviral activity. However, it was notable that inactivation of HK2 significantly increased 301 HCMV-mediated plaque formation in the absence of TNFα treatment (Fig 4j) , suggesting that HK2 302 could be playing a role in intrinsic anti-viral defense. Future work should explore this possibility, 303 as well as the possibility that HK2 induction is contributing to other aspects of TNFα-modulated 304 innate immunity, for example, processing or presentation of viral antigens.

Hif1α is a central regulator of glycolytic gene expression and was implicated in TNFα-307 mediated induction of HK2 in murine skeletal muscle cells 37 , raising the possibility that Hif1α is 308 important for TNFα-mediated induction of glycolysis. Our data suggest that Hif1α is dispensable 309 for TNFα-mediated induction of lactate secretion and inhibition of HCMV replication (Fig 4i & 4j) . 

In addition to activation of glycolysis, we find that TNFα induces the accumulation UDP- 

Potential secondary effects of losing STAT1 notwithstanding, it is still plausible that in addition to 357 providing UDP-sugar subunits to support glycosylation, glycolysis contributes to TNFα's anti-viral 358 activity via other downstream metabolic activities. In this regard, many questions still remain about the molecular fate of glycolytically-derived carbon and how these pathways could contribute to 360 TNFα's anti-viral activity.

Our results indicate that TNFα-induced metabolic remodeling is important for its ability to 

For all experiments where cells were treated with TNFα and/or inhibitors, cells were grown to 399 confluence. Twenty four hours prior to infection, the medium was replaced with serum-free 400 DMEM supplemented with 1% PenStrep and appropriate compounds as indicated. 

Plaques were allowed to develop for 10 days and total number of plaques in each well was 426 counted using a fluorescent microscope. For each indicated experimental condition, total plaque 427 count of each well was normalized to the average plaque count of the control condition. 

For quantification of western blots GAPDH, HK2 and Glut1 (Fig. 4f) , a single lysate sample of 461 HFFs treated with vehicle or TNFα for 24 hr was run on three independent gels and immunoblotted 462 for GAPDH, HK2 and Glut1 as described above. Band intensities were determined using Image 

HFFs were grown to confluence in a 12-well TC-treated plate and treated with 500 μL indicated 541 treatment master mix for 24 hours. Medium was harvested from each well and stored at -80C. To 542 measure lactate in the medium, a standard curve was prepared using a 16 mM lactate standard 543 as the most concentrated standard and serially diluting this most concentrated standard 1:2 8x.

Medium samples were diluted 1:64 in PBS. Samples and standards were loaded onto the same 545 MS run and resulting MS intensity data of the standards was used to generate a standard curve.

Standards that began to plateau or fell below the limit of detection (3x the value of the average 547 blank) were discarded from the standard curve. 

For metabolomics data analysis, LC-MS/MS intensity values were imported to Metaboanalyst 580 5.0 61 . Data was mean-centered and divided by the standard deviation (SD) of each variable. For 581 principal component analysis (Fig 1a & Fig 3a) , each dot represents metabolomics data of one 582 biologically independent sample. Shaded ellipses represent 95% confidence intervals. PC1 and 583 PC2 refer to the amount of total variation observed between samples that can be attributed to 584 segregation along that principal component. Hierarchical clustering maps (Fig 1b & Fig 3b) 

HFFs were grown to confluence in 10 cm dishes in growth medium. Medium was replaced with 594 serum-free medium containing 10 mM HEPES for 24 hours. Cells were then treated with 7 mL 595 indicated treatment medium containing 12 C-Glucose (4.5 g/L) and 10 mM HEPES for 19 hours. At 596 19 hours, medium was replaced with 7 mL indicated treatment medium containing U-13 C-Glucose

(Cambridge Isotopes #CLM-1396-1) (4.5 g/mL). Metabolites were extracted from cells as 

For principal component analysis (Figure 5a ) each dot represents proteomics data of one 620 biologically independent sample. Shaded ellipses represent 95% confidence intervals. PC1 and 621 PC2 refer to the amount of total variation observed between samples that can be attributed to 622 segregation along that principal component.

To observe the differences in abundance of metabolic enzymes between vehicle and TNFα 625 treated cells, a list of genes involved in metabolism was retrieved from the UniProt Database on

August 31 st , 2021 to yield 4,432 human genes involved in metabolism (Supplementary Table 4 .1).

This list of genes was scanned against our proteomics data set of 3,780 proteins using a custom Figure 1 ) each dot represents proteomics data of one biologically independent sample. Shaded 632 ellipses represent 95% confidence intervals. PC1 and PC2 refer to the amount of total variation 633 observed between samples that can be attributed to segregation along that principal component.

Hierarchical clustering maps (Fig 4a) 

For the analysis a specific protein of interest, normalized protein abundance was calculated by 642 dividing each sample relative protein abundance by the average of the vehicle-treated relative 643 protein abundance (Fig. 4c & 6a) . Statistics were performed in GraphPad Prism v9.1.0.

To generate a list of proteins more abundant in TNFα treatment compared to TNFα+2DG co- (Fig 5c) .

Similarly, a list of proteins more abundant in TNFα+2DG co-treatment compared to TNFα Figure 2 . TNFα treatment induces glycolytic flux. a HFFs were treated with TNFα (10 ng/mL, red) or vehicle (black) for 0, 4, 12 and 24 hr prior to extraction and LC-MS/MS analysis (mean ± SD plotted, n=3). Solid arrows represent direct metabolite conversions while dashed arrows represent indirect conversions. Single-headed arrows represent irreversible conversions while double-headed arrows represent reversible conversions. (b/c) HFFs were treated with TNFα (10 ng/mL, light red or 100 ng/mL, dark red) or vehicle (black) for 24 hr. Media harvested from each sample were analyzed for b glucose consumption and c lactate secretion. (mean ± SD, n=3, with FDR adjusted ANOVA p-values, *p<0.05, **p<0.01, ***p<0.001). Figure 3 . Glycolytic flux is required for TNFα to induce its anti-viral state. (a-c) HFFs treated with TNFα (10 ng/mL, red), 2DG (20 mM, blue), TNFα+2DG (purple), or vehicle (black) for 24 hr (n=4). Metabolites were extracted from cells and analyzed by LC-MS/MS (mean ± SD, n=4). Metabolite data analyzed via a PCA or b Hierarchical clustering with metabolite values depicted as Z-scores from min (blue) to max (red). c Relative metabolite abundance. d HFFs treated with TNFα (10 ng/mL, red) in the presence or absence of glucose (Glc ±) or 2-deoxyglucose (2DG, 20 mM) for 24 hr prior to a media change with fresh viral adsorption media containing glucose, but without inhibitors, and HCMV-GFP (MOI=0.5). Infected cells were identified by GFP expression 24 hr post-infection and quantified (n=12, mean ± SD). e HFFs pretreated as indicated for 24 hr prior to media change with fresh viral adsorption media containing glucose, but without inhibitors, and a known number of HCMV-GFP infectious particles. Viral plaques were quantified (n=6, relative mean ± SD). f Cells were pre-treated as in (e), infected with HCMV (MOI=3), and processed for western analysis at the indicated times post-infection. (g-h) Cells were pretreated as in (e), infected with g OC43 (MOI=3) or h SARS-CoV2 (MOI=0.01) and harvested 48 hr post-infection for RT-qPCR analysis (mean ± SD, n=6 (g) or n=3 (h)). p-values were calculated using two-way ANOVA and FDR corrected; *p<0.05, **p<0.01, ***p<0.001. Figure 4 . TNFα treatment induces HK2 expression to support glycolytic flux. (a-f) HFFs were treated with TNFα (10 ng/mL, red) or vehicle (black) for 24 hr, unless otherwise indicated. (a-c) Cells were harvested for proteomics analysis. a Hierarchical clustering of proteins involved in metabolism. Protein abundance values are depicted as Z-scores from min (blue) to max (red). b Schematic of metabolites and enzymes involved in glycolysis significantly dysregulated by TNFα treatment. Red = significantly more abundant, blue = significantly less abundant. c Proteomics data for Glut1, HK2, PFK-M and TIGAR normalized to vehicle-treated (mean ± SD, n=3). (d/e/g/f) Cells were harvested at the indicated times post TNFα treatment for RT-qPCR analysis of d HK2, e Glut1 and g Hif1α mRNA or f western analysis as indicated. Band intensities quantified and normalized to the intensity of their respective GAPDH bands. (h-j) Cells treated with CRISPR Cas9-RNP containing guides for HK2, Hif1a, or a non-target guide (ntg) to generate knockout (KO) cell lines. KO cells harvested for h western analysis as indicated. KO cells treated with TNFα (10 ng/mL, red) or vehicle (black) for 24 hr, i media analyzed for lactate secretion. j KO cells pre-treated with 2DG (20 mM, black) and TNFα (10 ng/mL) as indicated prior to media change with fresh viral adsorption media, without inhibitors, containing a known number of HCMV-GFP infectious particles. Viral plaques were quantified and plotted as indicated. d mean ± SD, n=3, two-tailed unpaired ttest, *p<0.05, **p<0.01, ***p<0.001. c/e/g mean ± SD, n=3; i mean ± SD, n=4; j mean ± SD n=15 with FDR-adjusted p-values determined using 2way ANOVA followed by two-stage step-up method of Benjamini, Krieger and Yekutieli *p<0.05, **p<0.01, ***p<0.001. 

HFFs were treated with TNFα (10 ng/mL, red), 2DG (20 mM, blue), TNFα+2DG (purple) or vehicle (black) for 24 hr. Cells were harvested and analyzed by LC-MS/MS for protein abundance. a PCA of relative protein abundance from proteomic results. b Ontology analysis of TNFα-induced proteins that were significantly decreased upon co-treatment with 2DG. c Abundance of proteins belonging to the Response to Cytokine ontology [GO:0034097] (mean ± SD, n=3).

Vehicle TNFα (+) TNFα+2DG

Provisional Mortality Data

Pathogenesis of human cytomegalovirus infection and 679 cellular targets

Cytomegalovirus. In Fields' Virology

Pathogenic human coronavirus infections: causes and 686 consequences of cytokine storm and immunopathology

Immune activation: the role of pro-inflammatory 688 cytokines in inflammation, illness responses and pathological pain states

Antiviral effects of recombinant tumour necrosis factor in vitro

Decreased cytomegalovirus expression 692 following proinflammatory cytokine treatment of primary human astrocytes

Tumor Necrosis Factor Inhibits Spread of Hepatitis C Virus Among Liver Cells, Independent 696 From Interferons

The JAK/STAT signaling pathway

NF-kappa B and Rel proteins: evolutionarily conserved 700 mediators of immune responses

Intrinsic antiviral immunity

Antigen receptor-mediated changes in glucose metabolism in B lymphocytes: role of 704 phosphatidylinositol 3-kinase signaling in the glycolytic control of growth

Cutting edge: IL-4-mediated protection of primary B lymphocytes from apoptosis via 707

Stat6-dependent regulation of glycolytic metabolism

Enhancing CD8 T-cell memory by modulating fatty acid metabolism

Mitochondria are required for 712 antigen-specific T cell activation through reactive oxygen species signaling

HIF-1alpha is 716 essential for myeloid cell-mediated inflammation

Supplemental glutamine augments phagocytosis and reactive oxygen intermediate production by 719 neutrophils and monocytes from postoperative patients in vitro

The sedoheptulose kinase CARKL directs macrophage polarization 724 through control of glucose metabolism

Alternative macrophage activation and metabolism. Annual review of 726 pathology

Oxidative metabolism and PGC-1beta attenuate macrophage-729 mediated inflammation

Studies on the Biosynthesis of Nicotinamide Adenine Dinucleotide

Utilization of tryptophan, nicotinamide and nicotinic acid as 733 precursors for nicotinamide nucleotide synthesis in isolated rat liver cells

Macrophage de novo NAD(+) synthesis specifies immune function in 737 aging and inflammation

Control of glycolysis through regulation of PFK1: old 739 friends and recent additions

Cellular and developmental control of O2 742 homeostasis by hypoxia-inducible factor 1 alpha

Cloning of a human liver UDP-glucose pyrophosphorylase cDNA by 744 complementation of the bacterialgalUmutation

Isolation of the ALG5 locus encoding the UDP-746 glucose:dolichyl-phosphate glucosyltransferase from Saccharomyces cerevisiae

Cloning and expression of N-749 acetylglucosaminyltransferase I, the medial Golgi transferase that initiates complex N-linked 750 carbohydrate formation

N-(Phosphonacetyl)-l-Aspartate

State Analog Inhibitor of Aspartate Transcarbamylase, Blocks Proliferation of Mammalian Cells in 753

SAR, species 755 specificity, and cellular activity of cyclopentene dicarboxylic acid amides as DHODH inhibitors

Effect of 6-758 aminonicotinamide on the pentose phosphate pathway: 31P NMR and tumor growth delay studies

Non-charged thiamine analogs as inhibitors of enzyme transketolase

Inhibition of mucin glycosylation by aryl-N-766 acetyl-α-galactosaminides in human colon cancer cells

Effect of O-glycosylated mucin on invasion and 769 metastasis of HM7 human colon cancer cells

TNF-alpha-induced NF-771 kappaB activation stimulates skeletal muscle glycolytic metabolism through activation of HIF-1alpha

Isozymes of mammalian hexokinase: structure, subcellular localization and 774 metabolic function

Hexokinase II integrates energy metabolism and cellular protection

Akting on mitochondria and TORCing to autophagy

Hypoxia-Inducible Factor 1alpha (HIF1alpha) Suppresses Virus

Replication in Human Cytomegalovirus Infection by Limiting Kynurenine Synthesis

Kynurenine pathway metabolites in humans: disease and healthy 780

The kynurenine system and immunoregulation

Glycosylation in cellular mechanisms of health and disease

Role of glycosylation in nucleating protein folding and stability

Glycosylation and the immune 788 system

Mammalian glycosylation in immunity

inducible MxB protein inhibits HIV-1 infection

The large 794 form of human 2',5'-Oligoadenylate Synthetase (OAS3) exerts antiviral effect against Chikungunya virus

Modulation of hepatitis C virus release by the interferon-induced protein BST-2/tetherin

Structural basis of HIV-1 tethering to 801 membranes by the BST-2/tetherin ectodomain

Complex roles of Stat1 in 803 regulating gene expression

Pharmacologic profiling reveals lapatinib as a novel antiviral against SARS-CoV-2 in vitro

Functional map of human cytomegalovirus AD169 defined by 809 global mutational analysis

The Human Cytomegalovirus 813 UL38 protein drives mTOR-independent metabolic flux reprogramming by inhibiting TSC2

Resp. to ER stress

Chaperone cofactor-dep, prot. refolding (GO:0051085) cell resp. to unfolded prot

GO:0051084) cell resp. to topologically incorrect prot. (GO:0035967) cell prot

GO:1903894) ubiquitin-dependent ERAD pathway (GO:0030433) cell resp

GO:0006986) receptor-med. endocytosis (GO:0006898) -log

ng/mL) in the presence and absence of 2DG (20 mM) for 24 hr. Cells harvested and analyzed for protein abundance (Supplementary Table 4)

 Figure 6 . TNFα treatment induces glycosylation precursor turnover. HFFs were treated with TNFα (10 ng/mL, red) or vehicle (black) for 24 hr. a Cells harvested and analyzed by LC-MS/MS for protein abundance. Normalized protein abundance of UTP-glucose-1-phosphate uridylyl transferase (UGP2), Dolichyl-phosphate beta-glucosyltransferase (ALG5), and Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosamine transferase (MGAT1) (mean ± SD, n=3). b Metabolites extracted from cells and analyzed by LC-MS/MS for UDP-Glucose (UDP-Glc) and UDP-N-Acetyl Glucosamine (UDP-GlcNAc) intracellular concentrations (mean ± SD, n=3). (c/d) HFFs treated with TNFα (10 ng/mL, red) or vehicle (black) for 19 hours in media containing unlabeled 12 C-glucose prior to media change with media containing U-13 C-glucose. Cellular extracts were harvested at t=0, 1, 2 and 5 hr post-label addition. C UDP-Glc or d UDP-GlcNAc intracellular isotopologue abundances were quantified by LC-MS/MS (mean ± SD, n=3). Solid lines represent intracellular abundances of unlabeled 12 C metabolite species, dashed lines represent intracellular abundances of 13 C-labeled metabolite species. M refers to the 12 C unlabeled species and M+n represents detection of a 13 C-labeled species where n represents the number of additional mass units detected by mass spec a/b FDR-adjusted p-values were determined using 2-way ANOVA followed by two-stage step-up method of Benjamini, Krieger and Yekutieli; ns = not significant, *p<0.05, **p<0.01, ***p<0. Table  4 ). Statistical parameters applied to proteomics data, described in materials and methods, to generate a list of proteins significantly induced by TNFα treatment but depleted in cells co-treated with TNFα and 2DG. Protein list submitted for Gene Ontology (GO) analysis (Fig. 6b ) and scanned against databases of known glycosylated proteins (described in materials and methods) or 'Response to Cytokine Signaling' [GO:0034097] (Supplementary Table 4 .2). Venn Diagram represents overlap of proteins involved in cytokine signaling (yellow) and glycosylated (blue).